C Lucchinetti

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Meningeal and cortical grey matter pathology in multiple sclerosis
    Bogdan F Gh Popescu
    Department of Anatomy and Cell Biology, University of Saskatchewan, 107Wiggins Road, Saskatoon, SK S7N 5E5, Canada
    BMC Neurol 12:11. 2012
  2. ncbi request reprint A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases
    C Lucchinetti
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    Brain 122:2279-95. 1999
  3. ncbi request reprint Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment
    C Lucchinetti
    aDepartment of Neurology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Curr Opin Neurol 14:259-69. 2001
  4. ncbi request reprint A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica
    Claudia F Lucchinetti
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Brain 125:1450-61. 2002
  5. pmc Inflammatory cortical demyelination in early multiple sclerosis
    Claudia F Lucchinetti
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    N Engl J Med 365:2188-97. 2011
  6. ncbi request reprint Bright red nuclei
    Sean J Pittock
    Department of Neurology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Neurology 62:619. 2004
  7. ncbi request reprint The pathology of primary progressive multiple sclerosis
    Claudia Lucchinetti
    Department of Neurology, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Mult Scler 10:S23-30. 2004
  8. ncbi request reprint Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis
    Shanu F Roemer
    Department of Neurology, Mayo Clinic, College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Brain 130:1194-205. 2007
  9. ncbi request reprint Amphiphysin autoimmunity: paraneoplastic accompaniments
    Sean J Pittock
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Neurol 58:96-107. 2005
  10. ncbi request reprint The pathology of MS: new insights and potential clinical applications
    Sean J Pittock
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    Neurologist 13:45-56. 2007

Research Grants

  1. Genetic Determinants of Pathologic Heterogeneity in MS
    Claudia Lucchinetti; Fiscal Year: 2007
  2. Mechanisms of Multiple Sclerosis Tissue Pathology
    Claudia Lucchinetti; Fiscal Year: 2009
  3. Mechanisms of Multiple Sclerosis Tissue Pathology
    Claudia Lucchinetti; Fiscal Year: 2010

Detail Information

Publications62

  1. pmc Meningeal and cortical grey matter pathology in multiple sclerosis
    Bogdan F Gh Popescu
    Department of Anatomy and Cell Biology, University of Saskatchewan, 107Wiggins Road, Saskatoon, SK S7N 5E5, Canada
    BMC Neurol 12:11. 2012
    ....
  2. ncbi request reprint A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases
    C Lucchinetti
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    Brain 122:2279-95. 1999
    ..The profound heterogeneity in extent and topography of OG destruction in active demyelinating lesions suggests that in subsets of multiple sclerosis patients, myelin, mature OGs and possibly OG progenitors are differentially affected...
  3. ncbi request reprint Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment
    C Lucchinetti
    aDepartment of Neurology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Curr Opin Neurol 14:259-69. 2001
    ..This complex pathogenesis is reflected in the variable response of multiple sclerosis patients to immunomodulatory therapy...
  4. ncbi request reprint A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica
    Claudia F Lucchinetti
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Brain 125:1450-61. 2002
    ..Based on this study, future therapeutic strategies designed to limit the deleterious effects of complement activation, eosinophil degranulation and neutrophil/macrophage/microglial activation are worthy of further investigation...
  5. pmc Inflammatory cortical demyelination in early multiple sclerosis
    Claudia F Lucchinetti
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    N Engl J Med 365:2188-97. 2011
    ..Magnetic resonance imaging studies indicate that cortical damage occurs early in the disease...
  6. ncbi request reprint Bright red nuclei
    Sean J Pittock
    Department of Neurology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Neurology 62:619. 2004
  7. ncbi request reprint The pathology of primary progressive multiple sclerosis
    Claudia Lucchinetti
    Department of Neurology, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Mult Scler 10:S23-30. 2004
    ..This review will focus on the pathological aspects of PPMS and pathogenic implications. A better understanding of the differences in PPMS pathology and pathogenesis will lead to more effective treatment strategies...
  8. ncbi request reprint Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis
    Shanu F Roemer
    Department of Neurology, Mayo Clinic, College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Brain 130:1194-205. 2007
    ..These findings strongly support a role for a complement activating AQP4-specific autoantibody as the initiator of the NMO lesion, and further distinguish NMO from MS...
  9. ncbi request reprint Amphiphysin autoimmunity: paraneoplastic accompaniments
    Sean J Pittock
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Neurol 58:96-107. 2005
    ..01). Overall, a minority of women (39%) and men (12%) had stiff-man phenomena. Only 10% of women (some with lung carcinoma) and 4% of men fulfilled diagnostic criteria for stiff-man syndrome...
  10. ncbi request reprint The pathology of MS: new insights and potential clinical applications
    Sean J Pittock
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    Neurologist 13:45-56. 2007
    ..As the site of disease pathology, the MS lesion remains the target of attack for therapy. Therefore it is essential we better understand MS lesion evolution and its clinical as well as paraclinical correlates...
  11. ncbi request reprint Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments
    Sean J Pittock
    Department of Neurology, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
    Ann Neurol 53:580-7. 2003
    ....
  12. doi request reprint Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays
    Andrew McKeon
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Arch Neurol 66:1134-8. 2009
    ....
  13. doi request reprint Neuromyelitis optica and non organ-specific autoimmunity
    Sean J Pittock
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Arch Neurol 65:78-83. 2008
    ..Neuromyelitis optica (NMO) is often associated with other clinical or serological markers of non-organ-specific autoimmunity...
  14. pmc Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease
    Setty M Magaña
    Department of Neurology, Mayo Clinic College of Medicine, 200 First Ave SW, Rochester, MN 55902, USA
    Arch Neurol 66:964-6. 2009
    ..To our knowledge, this study is the first to compare NMO IgG serostatus among patients with fulminant central nervous system inflammatory demyelinating disease (CNS IDD)...
  15. ncbi request reprint Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis
    Dean M Wingerchuk
    Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
    Curr Opin Neurol 20:343-50. 2007
    ..We review recent progress in differentiating and understanding the disease mechanisms of acute disseminated encephalomyelitis, neuromyelitis optica, and classical multiple sclerosis...
  16. ncbi request reprint The spectrum of neuromyelitis optica
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Lancet Neurol 6:805-15. 2007
    ..The knowledge gained from further assessment of the exact role of NMO-IgG in the pathogenesis of neuromyelitis optica will provide a foundation for rational therapeutic trials for this rapidly disabling disease...
  17. doi request reprint Multiple sclerosis and the spectrum of CNS inflammatory demyelinating diseases
    Claudia F Lucchinetti
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Semin Neurol 28:3-6. 2008
  18. doi request reprint Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma
    Alyx B Porter
    Department of Neurology, Mayo Clinic Rochester, Rochester MN, USA
    Ann Neurol 63:662-7. 2008
    ..0). The majority of PCNSL patients who received corticosteroids before diagnosis did not experience significant radiographic change or require second biopsy for diagnosis...
  19. pmc Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration
    Isobel A Scarisbrick
    Program for Molecular Neuroscience, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Biol Chem 389:739-45. 2008
    ..These novel findings suggest that KLK1 and KLK6 may serve as serological markers of progressive MS and contribute directly to the development of neurological disability by promoting axonal injury and neuron cell death...
  20. doi request reprint Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues
    Fausto J Rodriguez
    Department of Laboratory Medicine and Pathology, Research Center, Mayo Clinic, Rochester, MN 55905, USA
    Lab Invest 88:1024-37. 2008
    ..LC-MS/MS represents a novel application for characterization of these deposits and is of diagnostic utility in addition to standard immunohistochemical analyses...
  21. doi request reprint Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri)
    Sean J Pittock
    Mayo Medical School College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Arch Neurol 67:1109-15. 2010
    ..However, the neurologic spectrum of ANNA-2 autoimmunity is broader, includes a syndrome of jaw dystonia and laryngospasm, and can be accompanied by lung carcinoma...
  22. doi request reprint Default mode network disruption secondary to a lesion in the anterior thalamus
    David T Jones
    Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 68:242-7. 2011
    ..To describe the neuroanatomical correlations of an isolated lesion in the anterior thalamus using functional imaging in a 40-year-old man with multiple sclerosis...
  23. ncbi request reprint NMO-IgG: a specific biomarker for neuromyelitis optica
    Brian G Weinshenker
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dis Markers 22:197-206. 2006
    ....
  24. ncbi request reprint Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN55905, USA
    Int J Radiat Oncol Biol Phys 66:1178-86. 2006
    ..The aim of this study was a retrospective assessment of neurotoxicity in patients with multiple sclerosis (MS) receiving external beam radiotherapy (EBRT) to the brain...
  25. ncbi request reprint Inflammatory transverse myelitis: evolving concepts
    Sean J Pittock
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Curr Opin Neurol 19:362-8. 2006
    ..Here we describe recent advances in inflammatory non-infectious transverse myelitis. Particular attention will be paid to the serum autoantibody marker NMO-IgG and its application to acute transverse myelitis...
  26. ncbi request reprint The pathology of multiple sclerosis
    Claudia F Lucchinetti
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurol Clin 23:77-105, vi. 2005
  27. ncbi request reprint A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
    Vanda A Lennon
    Department of Neurology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Lancet 364:2106-12. 2004
    ..We assessed the capacity of a putative marker for neuromyelitis optica (NMO-IgG) to distinguish neuromyelitis optica and related disorders from multiple sclerosis...
  28. ncbi request reprint The pathology of multiple sclerosis: evidence for heterogeneity
    Yazmin Morales
    Clinical Research Training Program, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, Minnesota, USA
    Adv Neurol 98:27-45. 2006
    ....
  29. ncbi request reprint Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis
    Brian G Weinshenker
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Neurol 59:566-9. 2006
    ..We investigated whether neuromyelitis optica (NMO) IgG seropositivity at the initial presentation of longitudinally extensive transverse myelitis (LETM) predicts relapse of myelitis or development of optic neuritis...
  30. ncbi request reprint Brain abnormalities in neuromyelitis optica
    Sean J Pittock
    Department of Neurology, Laboratory Medicine and Pathology, Radiology, and Immunology, Mayo Clinic College of Medicine, Rochester, Minn, USA
    Arch Neurol 63:390-6. 2006
    ..We have, however, frequently encountered patients with a well-established diagnosis of NMO in whom either asymptomatic or symptomatic brain lesions develop suggesting that the diagnostic criteria for NMO should be revised...
  31. ncbi request reprint Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression
    Sean J Pittock
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905 0001, USA
    Arch Neurol 63:964-8. 2006
    ..Although it is conventionally believed that the brain is spared, brain imaging abnormalities are not uncommon in patients with NMO...
  32. pmc Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2
    Shannon R Hinson
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Exp Med 205:2473-81. 2008
    ..Thus, binding of NMO-IgG to astrocytic AQP4 initiates several potentially neuropathogenic mechanisms: complement activation, AQP4 and EAAT2 down-regulation, and disruption of glutamate homeostasis...
  33. ncbi request reprint CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis
    Orhun H Kantarci
    Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Neuroimmunol 169:137-43. 2005
    ..Furthermore it does not segregate with patterns of immunopathology in MS. We did not find an association between CCR5*Delta32 mutation and disease severity and age of onset in MS...
  34. ncbi request reprint Not every patient with multiple sclerosis should be treated at time of diagnosis
    Sean J Pittock
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 63:611-4. 2006
  35. doi request reprint Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica
    Andrew McKeon
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Muscle Nerve 39:87-90. 2009
    ..0001. The coexistence of NMO and MG should be considered in atypical or refractory presentations of either disorder...
  36. pmc Multiple sclerosis with predominant, severe cognitive impairment
    Nathan P Staff
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 66:1139-43. 2009
    ..To describe the characteristics of multiple sclerosis (MS) presenting with severe cognitive impairment as its primary disabling manifestation...
  37. doi request reprint The pathological spectrum of CNS inflammatory demyelinating diseases
    Wei Hu
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Semin Immunopathol 31:439-53. 2009
    ..Herein, we review the clinicopathologic features of these CNS inflammatory demyelinating disorders and discuss recent advances in understanding their immunopathogenesis...
  38. pmc Radiation-induced optic neuritis after pituitary adenoma radiosurgery in a patient with multiple sclerosis: case report
    Thomas B Daniels
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Neurooncol 93:263-7. 2009
    ..To describe a rare case of optic neuritis onset after Gamma Knife stereotactic radiosurgery...
  39. pmc Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis
    Nathan P Young
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Brain 133:333-48. 2010
    ....
  40. ncbi request reprint Pathological heterogeneity of idiopathic central nervous system inflammatory demyelinating disorders
    C Lucchinetti
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Curr Top Microbiol Immunol 318:19-43. 2008
    ....
  41. doi request reprint Acute disseminated encephalomyelitis: current understanding and controversies
    Nathan P Young
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Semin Neurol 28:84-94. 2008
    ..We review pathological differences between ADEM and MS in terms of their utility in the diagnosis of ADEM. Finally, we present a practical approach for management of patients suspected of having ADEM when the diagnosis is uncertain...
  42. ncbi request reprint Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions
    E M Frohman
    Department of Neurology, University of Texas Southwestern Medical Center at Dallas, 75235, USA
    Arch Neurol 62:1345-56. 2005
    ....
  43. pmc Absence of cortical demyelination in neuromyelitis optica
    B F Gh Popescu
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 75:2103-9. 2010
    ..NMO is an autoimmune inflammatory demyelinating disease that specifically targets aquaporin-4-rich regions of the CNS. Since aquaporin-4 is highly expressed in normal cortex, we anticipated that cortical demyelination may occur in NMO...
  44. pmc Beneficial plasma exchange response in central nervous system inflammatory demyelination
    Setty M Magaña
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Arch Neurol 68:870-8. 2011
    ..Despite the approximately 45% PLEX response rate reported among patients with CNS-IDD, determinants of interindividual differences in PLEX response are not well characterized...
  45. pmc A case of multiple sclerosis presenting with inflammatory cortical demyelination
    B F Gh Popescu
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 76:1705-10. 2011
    ....
  46. pmc Childhood-onset multiple sclerosis with progressive dementia and pathological cortical demyelination
    Reem F Bunyan
    Department of Neurology, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
    Arch Neurol 68:525-8. 2011
    ..To describe a case of childhood-onset progressive multiple sclerosis with dementia and evidence of extensive cortical demyelination from brain biopsy specimen...
  47. pmc Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications
    B F Gh Popescu
    Mayo Clinic, College of Medicine, Rochester, MN 55905, USA
    Neurology 76:1229-37. 2011
    ..Aquaporin-4 (AQP4) autoimmunity targets this region, resulting in intractable nausea associated with vomiting or hiccups in NMO...
  48. doi request reprint Intractable vomiting as the initial presentation of neuromyelitis optica
    Metha Apiwattanakul
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Neurol 68:757-61. 2010
    ..Our clinical, pathologic and neuroimaging observations suggest the aquaporin-4-rich area postrema may be a first point of attack in neuromyelitis optica...
  49. ncbi request reprint Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange
    Mark Keegan
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Lancet 366:579-82. 2005
    ..0001). Patients with multiple sclerosis with pattern II pathology are more likely to respond favourably to TPE than are patients with patterns I or III...
  50. ncbi request reprint Ornithine transcarbamylase deficiency presenting as encephalopathy during adulthood following bariatric surgery
    William T Hu
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Arch Neurol 64:126-8. 2007
    ..Whereas nutritional deficiencies are the most common cause of neurological symptoms, the unmasking of previously subclinical metabolic disorders can also lead to significant morbidity...
  51. ncbi request reprint Neuromyelitis optica: changing concepts
    Anu Jacob
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Neuroimmunol 187:126-38. 2007
    ..The development of animal models and further analysis of the association of NMO-IgG with disease severity and treatment response will elucidate the pathobiology of NMO...
  52. ncbi request reprint Gray matter involvement in multiple sclerosis
    Istvan Pirko
    Department of Neurology, University of Cincinnati, OH, USA
    Neurology 68:634-42. 2007
    ..However, continued studies of GM pathology as well as neuronal and axonal involvement in MS and related experimental models are necessary to better understand the etiology and pathogenesis of the degenerative components...
  53. ncbi request reprint Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis
    Imke Metz
    Department of Neuropathology, Georg August University, Gottingen, Germany
    Brain 130:1254-62. 2007
    ....
  54. pmc Myelin transcription factor 1 (Myt1) expression in demyelinated lesions of rodent and human CNS
    Adam C Vana
    Program in Neuroscience, Uniformed Services University of the Health Sciences, Bethesda, Maryland
    Glia 55:687-97. 2007
    ..These results suggesta potential role for Myt1 in the regeneration of oligodendrocyte lineage cells in response to demyelination...
  55. ncbi request reprint Widespread demyelination in the cerebellar cortex in multiple sclerosis
    Alexandra Kutzelnigg
    Center for Brain Research, Medical University of Vienna, Austria
    Brain Pathol 17:38-44. 2007
    ..Our data identify cortical demyelination as a potential substrate of cerebellar dysfunction in MS...
  56. doi request reprint Cortical demyelination in CNS inflammatory demyelinating diseases
    Hans Lassmann
    Neurology 70:332-3. 2008
  57. ncbi request reprint Expression of chemokine receptors CCR1 and CCR5 reflects differential activation of mononuclear phagocytes in pattern II and pattern III multiple sclerosis lesions
    Don J Mahad
    Department of Neurosciences, The Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Neuropathol Exp Neurol 63:262-73. 2004
    ..As judged by mononuclear phagocyte chemokine receptor expression, there appear to be distinct tissue environments in pattern II and III MS lesions...
  58. ncbi request reprint Evidence for pathogenic heterogeneity in multiple sclerosis
    Claudia F Lucchinetti
    Ann Neurol 56:308. 2004
  59. ncbi request reprint Cortical demyelination and diffuse white matter injury in multiple sclerosis
    Alexandra Kutzelnigg
    Center for Brain Research, Medical University of Vienna, Vienna, Austria
    Brain 128:2705-12. 2005
    ..With chronicity, diffuse inflammation accumulates throughout the whole brain, and is associated with slowly progressive axonal injury in the NAWM and cortical demyelination...
  60. ncbi request reprint Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis
    Christine Stadelmann
    Brain Research Center, Medical University of Vienna, Vienna, Austria
    Brain 128:979-87. 2005
    ..Due to their neuroprotective effects, the rim of periplaque tissue, where these proteins are expressed, may be resistant to further damage in an expanding lesion and may therefore remain as a layer of preserved myelinated tissue...
  61. ncbi request reprint The immunopathology of multiple sclerosis: an overview
    Hans Lassmann
    Centre for Brain Research, Medical University of Vienna, Vienna, Austria
    Brain Pathol 17:210-8. 2007
    ..This heterogeneity is reflected by different clinical manifestations of the disease, such as relapsing or progressive MS, and also explains at least in part the relation of MS to other inflammatory demyelinating diseases...
  62. pmc CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages
    Corinna Trebst
    Department of Neurosciences, The Lerner Research Institute, Cleveland, Ohio 44195, USA
    Am J Pathol 162:427-38. 2003
    ..CCR8 expression may also indicate a selective program of mononuclear phagocyte gene expression...

Research Grants5

  1. Genetic Determinants of Pathologic Heterogeneity in MS
    Claudia Lucchinetti; Fiscal Year: 2007
    ....
  2. Mechanisms of Multiple Sclerosis Tissue Pathology
    Claudia Lucchinetti; Fiscal Year: 2009
    ....
  3. Mechanisms of Multiple Sclerosis Tissue Pathology
    Claudia Lucchinetti; Fiscal Year: 2010
    ....